Table 2 Treatment, complications, and progress of patients with COVID-19 depending on hospital readmission.
From: Frequency, risk factors, and outcomes of hospital readmissions of COVID-19 patients
Treatments | No readmission n = 6839 | Missing | Readmission n = 298 | Missing | p | Overall missing |
|---|---|---|---|---|---|---|
Duration of invasive ventilation (median, IQR) | 10 (7–15) | 28 (0.4%) | 8 (6–16) | 1 (0.3%) | 0.966 | 29 (0.4%) |
Duration of noninvasive ventilation (median, IQR) | 4 (2–8) | 32 (0.5%) | 4 (3–8) | 1 (0.3%) | 0.612 | 33 (0.5%) |
Glucocorticoid treatment (n, %) | 2034 (29.7) | 53 (0.8%) | 114 (38.3) | 1 (0.3%) | 0.002 | 54 (0.8%) |
LMWH, prophylactic dose, during admission (n,%) | 5658 (82.7) | 0.9% (65) | 246 (82.6) | 5 (1.7%) | 0.791 | 70 (0.9%) |
Remdesivir (n, %) | 31 (0.5) | 86 (1.3%) | 1 (0.3) | 3 (1.0%) | 0.611 | 89 (1.2%) |
Interferon (n, %) | 784 (11.5) | 75 (1.0%) | 32 (10.7) | 0 | 0.674 | 75 (1.0%) |
Lopinavir/Ritonavir (n, %) | 4533 (66.3) | 32 (0.5%) | 163 (54.7) | 0 | < 0.001 | 32 (0.5%) |
Macrolide (n, %)1 | 4291 (62.7) | 44 (0.6%) | 153 (51.3) | 1 (0.3%) | < 0.001 | 45 (0.6%) |
Hydroxychloroquine (n, %) | 6128 (89.6) | 22 (0.3%) | 257 (86.2) | 0 | 0.075 | 22 (0.3%) |
Chloroquine (n, %) | 256 (3.7) | 56 (0.8%) | 10 (3.4) | 1 (0.3%) | 0.722 | 57 (0.8%) |
Tocilizumab (n, %) | 577 (8.4) | 55 (0.8%) | 19 (6.4) | 0 | 0.240 | 55 (0.8%) |
Complications (n, %) | ||||||
Bacterial pneumonia | 510 (7.5) | 17 (0.2%) | 31 (10.4) | 0 | 0.062 | 17 (0.2%) |
ARDS | 1481 (21.7) | 28 (0.4%) | 59 (19.8) | 2 (0.7%) | 0.435 | 30 (0.4%) |
Acute kidney injury | 539 (7.9) | 4 (< 0.1%) | 40 (13.4) | 0 | < 0.001 | 4 (< 0.1%) |
Acute cardiac injury | 220 (3.2) | 17 (0.2%) | 39 (13.1) | 0 | < 0.001 | 17 (0.2%) |
Stroke | 21 (0.3) | 16 (0.2%) | 1 (0.3) | 0 | 1.000 | 16 (0.2%) |
Sepsis | 136 (2.0) | 4 (< 0.1%) | 6 (2.0) | 0 | 1.000 | 4 (< 0.1%) |
Shock | 82 (1.2) | 39 (0.6%) | 5 (1.7) | 1 (0.3%) | 0.414 | 40 (0.6%) |
MOF | 37 (0.5) | 21 (0.3%) | 4 (1.3) | 0 | < 0.001 | 21 (0.3%) |
